Biomarin Pharmaceutical's stock plummeted 5.15% in pre-market trading on Tuesday.
The sharp decline follows news that investment firm Oppenheimer has reduced its price target on the stock to $95 from $98, indicating a more cautious outlook on the company's valuation.